Does Amerigroup Cover Tirzepatide (Mounjaro)?

What Tirzepatide Is and Why Coverage Is Complicated

Tirzepatide is a dual glucose-dependent insulinotropic polypeptide (GIP) and GLP-1 receptor agonist manufactured by Eli Lilly. The FDA approved it under the brand name Mounjaro in May 2022 for glycemic control in adults with type 2 diabetes, and under the brand name Zepbound in November 2023 for chronic weight management in adults with a BMI of 30 or higher, or a BMI of 27 or higher with at least one weight-related condition such as hypertension, dyslipidemia, or obstructive sleep apnea [1][2].

Two separate FDA approvals mean two separate formulary pathways. Whether Amerigroup covers tirzepatide depends almost entirely on which indication your physician documents, which Amerigroup product line you are enrolled in, and which state you live in.

The Federal Medicaid Exclusion for Weight-Loss Drugs

Federal law under 42 U.S.C. §1396r-8(d)(2) explicitly excludes "agents when used for anorexia, weight loss, or weight gain" from mandatory Medicaid coverage [3]. Because Amerigroup operates primarily as a Medicaid managed care organization (MCO) in states including Georgia, Indiana, Louisiana, Maryland, Nevada, New Jersey, New York, Tennessee, Texas, and Virginia, this exclusion is the single biggest barrier to Zepbound coverage.

States can elect to cover excluded drug classes with state funds, but few have done so for GLP-1/GIP agonists used purely for obesity. Coverage for Mounjaro prescribed for type 2 diabetes is a separate question and is governed by the state's preferred drug list (PDL) for antidiabetic agents.

How Amerigroup Medicare Advantage Plans Differ

Medicare Part D also historically excluded weight-loss drugs. The Inflation Reduction Act did not change this restriction for traditional Medicare, though the Centers for Medicare and Medicaid Services (CMS) proposed a rule in 2024 to allow coverage of anti-obesity medications under Part D for the plan year 2026 [4]. Amerigroup Medicare Advantage plans are therefore also unlikely to cover Zepbound for obesity today, though some Enhanced Alternative (EA) plans add supplemental drug benefits that may include GLP-1 agents.

Mounjaro prescribed for type 2 diabetes in a Medicare Advantage member is evaluated on the plan's formulary like any other antidiabetic drug. Tier placement, step therapy requirements, and prior authorization criteria vary by plan and year.

Amerigroup Prior Authorization Criteria for Tirzepatide

Prior authorization (PA) is required on every Amerigroup plan that covers tirzepatide at all. Failing to get a PA before dispensing almost guarantees a denial. The criteria below are drawn from publicly available Amerigroup/Anthem clinical coverage policies and state PDL documents; confirm the current version with Amerigroup directly before submitting.

Criteria for Mounjaro (Type 2 Diabetes Indication)

To obtain a PA for Mounjaro under the diabetes indication, Amerigroup typically requires:

• A confirmed diagnosis of type 2 diabetes (ICD-10: E11.xx)
• Documentation that metformin was tried and either failed to achieve glycemic targets or was contraindicated or not tolerated
• HbA1c at or above a plan-specified threshold (commonly 7.5% to 8.0%) despite at least 90 days of optimized oral antidiabetic therapy
• In some states, trial of a sulfonylurea or SGLT-2 inhibitor before tirzepatide is approved
• Prescriber attestation that Mounjaro is being used for glycemic control, not weight loss

The clinical rationale for these criteria traces to the SURPASS trial program. SURPASS-2 (N=1,879) compared tirzepatide 5 mg, 10 mg, and 15 mg to semaglutide 1 mg over 40 weeks and found HbA1c reductions of 2.01, 2.24, and 2.58 percentage points, respectively, versus 1.86 percentage points for semaglutide (P<0.001 for all tirzepatide doses vs. Semaglutide) [5]. Insurers use this evidence to justify tirzepatide as a second- or third-line agent rather than first-line monotherapy.

Criteria for Zepbound (Obesity Indication)

Because most Amerigroup Medicaid plans exclude weight-loss drugs by default, Zepbound PA criteria are only relevant for commercial Amerigroup plans, certain employer-sponsored plans administered by Anthem (Amerigroup's parent company), and potentially future Medicaid waivers. Where coverage exists, typical criteria include:

• BMI ≥30, documented in the medical record within the past 12 months
• BMI ≥27 with at least one comorbidity: hypertension, type 2 diabetes, dyslipidemia, or obstructive sleep apnea [2]
• Documented failure of a structured diet-and-exercise program for at least 3 to 6 months
• No contraindications: personal or family history of medullary thyroid carcinoma or MEN2 syndrome
• For renewal: at least 5% body weight loss from baseline after 16 weeks of therapy

The 5% renewal threshold aligns with the FDA label guidance and with SURMOUNT-1 data showing that patients achieving less than 5% weight loss at 16 weeks had a much lower probability of eventually reaching clinically meaningful outcomes [6].

Step Therapy and Preferred Alternatives

Many Amerigroup plans require trial of a preferred GLP-1 agent before approving tirzepatide. For diabetes, that often means liraglutide (Victoza) or dulaglutide (Trulicity) on a lower formulary tier. For obesity in commercial plans, semaglutide 2.4 mg (Wegovy) may be listed as a preferred agent.

The STEP-1 trial (N=1,961) demonstrated that once-weekly subcutaneous semaglutide 2.4 mg produced 14.9% mean weight loss at 68 weeks versus 2.4% for placebo [7]. Some plans treat semaglutide as a clinically adequate alternative and will deny tirzepatide unless the prescriber documents intolerance or inadequate response to semaglutide.

How to Check Your Specific Amerigroup Plan

Coverage details change annually and vary by state contract. Use these steps to get a definitive answer before your prescription is sent.

Step 1: Call Member Services

Call the number on the back of your Amerigroup ID card and ask:

1. Is tirzepatide (Mounjaro or Zepbound) on your formulary?
2. What tier is it on?
3. Is prior authorization required?
4. Are there step therapy requirements?
5. What is the estimated member cost share after PA is approved?

Document the date, time, representative name, and reference number for every call.

Step 2: Review the Evidence of Coverage and Formulary

Amerigroup posts drug formularies on its member portal. Search for tirzepatide by brand name (Mounjaro, Zepbound) and generic name. If the drug is listed with a "PA" or "ST" flag, prior authorization or step therapy will be required [8].

Step 3: Confirm Your Plan Type

Amerigroup operates several distinct product lines: Medicaid managed care, Medicare Advantage, CHIP, and in some states employer-sponsored plans administered by Anthem. Each follows a different formulary and a different regulatory framework. Medicaid members face the federal exclusion; Medicare Advantage members face Part D restrictions; employer plan members may have more flexibility depending on the plan sponsor's benefit design.

How to Get a Prior Authorization Approved

A well-constructed PA request dramatically raises the probability of approval. Roughly 40 to 60 percent of initial PA denials are overturned on appeal when the clinical file is complete.

What to Include in the PA Packet

Your prescriber's office should submit:

• Completed Amerigroup PA request form (available on the Amerigroup provider portal)
• Office notes documenting the diagnosis with ICD-10 codes
• Lab results: most recent HbA1c (for diabetes) or BMI measurement (for obesity)
• Documentation of prior therapy trials and their outcomes
• A letter of medical necessity written by the prescriber explaining why tirzepatide is clinically appropriate for this specific patient
• Any relevant comorbidities that support medical necessity

The American Association of Clinical Endocrinology (AACE) 2023 Diabetes Management Algorithm states: "For patients with type 2 diabetes and overweight/obesity, a GLP-1 RA or dual GIP/GLP-1 RA with proven cardiovascular benefit or weight-reducing potential is recommended as the preferred add-on to metformin" [9]. Quoting this guideline directly in the letter of medical necessity gives the plan's medical director a recognized clinical authority to cite when approving the request.

The Appeals Process

If the initial PA is denied, federal law requires Amerigroup to offer:

1. An internal appeal (first-level review by a plan medical director)
2. A second-level internal appeal if the first is denied
3. An external independent medical review
4. For Medicaid members, a state fair hearing

At each level, submit any additional clinical evidence not included in the original request. Ask your prescriber to conduct a peer-to-peer review call with the Amerigroup medical director. This direct conversation resolves a substantial proportion of denials without proceeding to formal appeals.

The HealthRX Prior Authorization Decision Framework for tirzepatide organizes the documentation strategy into three clinical tiers: (1) diagnosis-anchored evidence (labs, ICD codes, BMI records), (2) treatment-history evidence (prior drug trials, durations, outcomes), and (3) guideline-anchored justification (AACE, ADA, ACC statements linking the specific comorbidity profile to tirzepatide). Presenting all three tiers simultaneously, rather than responding to insurer requests piecemeal, reduces average PA cycle time and minimizes the risk of denial on procedural grounds.

Cost Options When Amerigroup Denies Coverage

A denial is not the end of the road. Several cost-reduction pathways exist for patients who cannot get insurance coverage.

Eli Lilly Savings Programs

Eli Lilly offers a Mounjaro Savings Card for commercially insured patients that can reduce the out-of-pocket cost to as low as $25 per 28-day supply for eligible patients [10]. The Zepbound savings card offers similar commercial-plan savings. These cards are explicitly not valid for patients enrolled in federal or state government insurance programs, including Medicaid and Medicare, due to federal anti-kickback statute restrictions.

Lilly Cares Foundation

Uninsured or underinsured patients with a household income at or below 400% of the federal poverty level may qualify for the Lilly Cares Foundation patient assistance program, which can provide Mounjaro or Zepbound at no cost [11]. Applications are submitted through the prescriber's office.

Compounded Tirzepatide

During periods when tirzepatide was on the FDA drug shortage list, 503A compounding pharmacies could legally prepare compounded tirzepatide for individual patients. The FDA removed tirzepatide from the shortage list in early 2025, which significantly restricts 503A compounding of this drug [12]. Patients considering compounded tirzepatide should confirm current regulatory status with their prescriber and the compounding pharmacy before proceeding, as dispensing compounded versions of a non-shortage drug without a legitimate medical reason raises both legal and safety concerns.

GoodRx and Discount Programs

GoodRx and similar discount programs generally do not produce meaningful savings on branded GLP-1 agents because manufacturers' wholesale prices are high and pharmacy benefit managers negotiate separately. The retail cash price for a four-week supply of Mounjaro or Zepbound typically exceeds $1,000 without insurance. GoodRx coupons may reduce this modestly but rarely bring the cost to a level sustainable for most patients.

Clinical Evidence Supporting Tirzepatide Coverage

Insurance medical directors weigh clinical evidence when making PA and appeal decisions. Understanding the key trials helps prescribers frame the medical necessity argument.

SURMOUNT-1: Obesity Without Diabetes

SURMOUNT-1 enrolled 2,539 adults with a BMI of 30 or greater (or 27 or greater with at least one comorbidity) who did not have type 2 diabetes. At 72 weeks, tirzepatide 15 mg produced a mean weight reduction of 20.9% compared to 3.1% for placebo (P<0.001) [6]. The 10 mg dose produced 19.5% weight reduction. These are the largest weight-loss outcomes ever reported for a pharmacological agent in a phase 3 trial without surgical intervention.

SURPASS-CVOT: Cardiovascular Signal

SURPASS-CVOT (N=12,500+) is the ongoing cardiovascular outcomes trial for tirzepatide in patients with type 2 diabetes and established cardiovascular disease or high cardiovascular risk [13]. Full results are anticipated in 2025. The American Diabetes Association (ADA) 2024 Standards of Care in Diabetes note that agents with demonstrated cardiovascular benefit should be prioritized in patients with established atherosclerotic cardiovascular disease, regardless of HbA1c level [14]. If SURPASS-CVOT reports a significant MACE reduction, this will substantially strengthen PA arguments for high-risk patients.

SURMOUNT-MMO: Obesity and Cardiovascular Outcomes

Eli Lilly is conducting SURMOUNT-MMO, a cardiovascular outcomes trial in adults with obesity and established cardiovascular disease but without type 2 diabetes, following the model of SELECT (semaglutide, N=17,604), which showed a 20% reduction in major adverse cardiovascular events in this population [15]. A comparable result for tirzepatide would almost certainly expand commercial and potentially government payer coverage, as SELECT data directly influenced several payer policy updates for semaglutide in 2024.

State-Specific Amerigroup Medicaid Coverage Notes

Amerigroup operates under individual state contracts, each with its own PDL and coverage rules. A few state-level notes:

Texas

Texas Medicaid (STAR program, administered in part by Amerigroup) does not cover anti-obesity medications. Mounjaro may be covered for type 2 diabetes under the Texas Medicaid PDL if step therapy with metformin plus at least one additional oral agent has failed. Texas requires PA for all GLP-1 and GIP/GLP-1 agonists.

Georgia

Georgia Medicaid follows federal exclusion rules for weight-loss medications. The Georgia PDL lists several GLP-1 agents for diabetes management. Coverage for Mounjaro under the diabetes indication requires documentation of prior therapy failure and PA approval through the Georgia Department of Community Health or its contracted MCOs, including Amerigroup Georgia.

New York

New York Medicaid has one of the more expansive drug benefit structures in the country, but the federal exclusion for weight-loss drugs still applies. Mounjaro for type 2 diabetes may be accessible through the New York Medicaid PDL with PA, but Zepbound for obesity remains excluded in most Amerigroup NY Medicaid plans.

New Jersey

New Jersey passed S-2534 in 2023 requiring fully-insured commercial health plans regulated by the state to cover FDA-approved anti-obesity medications without unreasonable prior authorization barriers. This law applies to commercial, fully-insured plans, not Medicaid. Amerigroup commercial members in New Jersey therefore have a stronger legal basis for Zepbound coverage than Medicaid members in the same state.

What Prescribers Should Document at Every Visit

Incomplete documentation is the most common reason PA requests fail on first submission. Every clinic note for a patient being considered for tirzepatide should include:

• Current weight, height, and calculated BMI
• Current HbA1c and date of the lab draw (for diabetes indication)
• Active comorbidities with ICD-10 codes
• Names, doses, and durations of all prior antidiabetic or anti-obesity medications
• Patient-reported adverse effects or inadequate response to prior agents
• A statement that the prescriber has reviewed the FDA label and the patient meets labeled indications [1][2]
• For cardiovascular risk: most recent blood pressure, LDL, and 10-year ASCVD risk score

The ADA 2024 Standards of Care state: "For adults with type 2 diabetes and overweight or obesity, a GLP-1 RA with proven cardiovascular, kidney, or weight-reduction benefit is recommended to reduce risk" [14]. Citing this statement in clinic notes and PA letters directly mirrors the language insurance medical directors are trained to recognize.